Home Alzheimer’s Disease Researchers Plan to Evaluate CORVax12 Vaccine in Phase I Clinical Trial for...

Researchers Plan to Evaluate CORVax12 Vaccine in Phase I Clinical Trial for COVID-19

Providence Cancer Institute at Providence St. Joseph Health is pursuing a first-in-human phase I clinical trial of CORVax12, a novel DNA-encodable, investigational vaccine, which is intended to act as a prophylactic vaccine to prevent coronavirus disease 2019 (COVID-19), according to OncoSec, the vaccine’s developer.

The CORVax12 vaccine approach combines the co-administration of tavokinogene telseplasmid (interleukin-12 plasmid; IL-12; TAVO) with a DNA encodable version of the SARS-CoV-2 spike or “S” glycoprotein, which was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center to enhance immunogenicity of the component.

“Previous vaccine efforts against coronaviruses, including the SARS coronavirus, have focused on the S glycoprotein, which facilitates interaction with the host cell through binding to the ACE2…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Conducting a survey research, regarding Genetic tests for cancer. : braincancer

I am a Service Design Student at the Royal College of Art, London. I am working with the NHS Genomics, the scope of the...

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

Recent Comments